DrugDashboards

Bleomycin

Bleomycin · BLEOMYCIN SULFATE 30 [USP'U]/1 · Injection, Powder, Lyophilized, For Solution · Intramuscular; Intrapleural; Intravenous; Subcutaneous · Hikma Pharmaceuticals USA Inc.

NDC 00143-9241-01 · 1 VIAL in 1 BOX, UNIT-DOSE / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL · ANDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$106.10
Reported to Texas DSHS · 2026 annual filing · Hikma Pharmaceuticals USA Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 15 UNITS
$24.838
HCPCS J9040 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$2,735
73 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for bleomycin (injectable) in the next 90 days

sterile injectable · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA065042
TE code
AP
Approval date
Oct 17, 2001
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class III · TerminatedAug 5, 2021
    Hikma Pharmaceuticals USA Inc.Labeling: Not elsewhere classified: Mislabeling

Manufacturers of Bleomycin (Injection, Powder, Lyophilized, For Solution)

LabelerStrengthFirst seenLast seen
Hospira, Inc.BLEOMYCIN SULFATE 15 [USP'U]/1Jul 15, 2026Sep 3, 2026
Hikma Pharmaceuticals USA Inc.BLEOMYCIN SULFATE 15 [USP'U]/1Jul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.BLEOMYCIN SULFATE 30 [USP'U]/1Jul 15, 2026Sep 2, 2026
Hospira, Inc.BLEOMYCIN SULFATE 30 [USP'U]/1Jul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Bleomycin — NDC 00143-9241-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00143924101.

Free to cite with attribution — see how the data is put together.